EMN

Eastman Chemical Company - 10-Q Summary (Q2 2006)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2006, and the first six months of 2006. Eastman Chemical Company is a large accelerated filer engaged in the production of specialty chemicals, polymers, and fibers. The company operates through five reportable segments: Coatings, Adhesives, Specialty Polymers and Inks (CASPI); Fibers; Performance Chemicals and Intermediates (PCI); Performance Polymers; and Specialty Plastics (SP). In Q1 2006, the company realigned its organizational structure, eliminating interdivisional sales revenue and operating earnings from segment reporting.

Key Financial Metrics

Note: Free Cash Flow calculated as Operating Cash Flow ($163M) less Capital Expenditures ($169M) = -$6M for YTD 2006.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 10% in Q2 and 6% YTD compared to 2005, driven primarily by higher selling prices (passing through raw material/energy costs) and increased volume.
• Profitability Decline: Net earnings decreased significantly (45% in Q2, 40% YTD). This decline is largely attributable to the absence of a $171 million pre-tax gain from the sale of the Genencor equity investment in Q2 2005 and $46 million in early debt extinguishment costs incurred in 2005.
• Margin Compression: Gross margins declined from 21% to 18% in Q2 due to reduced margins in the Performance Polymers segment, where higher raw material costs (propane, paraxylene) were not fully offset by price increases.
• Segment Performance:
  • Fibers: Strong performance with operating earnings up 30% (Q2) and 34% (YTD) due to strong demand for acetate tow.
  • Performance Polymers: Significant decline in operating earnings (down 76% Q2, 78% YTD) due to lower selling prices for PET polymers and higher input costs.
  • CASPI & PCI: Modest earnings growth or stability despite higher input costs.

Guidance, Outlook, and Risks

• 2006 Outlook: Management expects full-year net earnings per share to follow a typical seasonal pattern (60% in H1, 40% in H2). They anticipate continued volatility in raw material and energy costs, with R&D expenses at approximately 3% of revenue and an effective tax rate of ~35%.
• Capital Expenditures: Expected to reach up to $450 million in 2006, exceeding depreciation and amortization (~$300 million). Major projects include the completion of the IntegRex PET facility in South Carolina and a copolyester intermediates expansion.
• Liquidity: The company maintains $890 million in credit facilities ($700M revolving, $148M Euro). Cash priorities include dividends, growth initiatives, and pension contributions ($75M expected for 2006).
• Subsequent Event: On July 24, 2006, the company agreed to sell its Arkansas-based subsidiary (Batesville facility) for $75 million, expected to close in Q4 2006.
• Risks: Key risks include raw material availability and cost volatility, foreign exchange fluctuations, and the competitive position in the PET polymers market. The company is also subject to ongoing asbestos and sorbates litigation, though management does not expect a material adverse effect.

Investor Verification Checklist

• Genencor Impact: Verify the non-recurring nature of the 2005 earnings boost ($171M gain) to accurately assess normalized earnings power.
• Performance Polymers Margin: Monitor the ability to pass on raw material costs in the PET segment, which drove the majority of the operating earnings decline.
• Capital Spending Execution: Track the completion of the IntegRex facility and the $450M capex budget against cash flow generation.
• Arkansas Divestiture: Confirm the closing of the $75M Batesville facility sale and its impact on the PCI segment's future results.
• Pension Funding: Verify the $75M pension contribution plan for 2006 and its impact on free cash flow.